Alanyl-glutamine consumption modifies the suppressive effect of L-asparaginase on lymphocyte populations in mice

Piyawan Bunpo, Betty Murray, Judy Cundiff, Emma Brizius, Carla J. Aldrich, Tracy G. Anthony

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Asparaginase (Elspar) is used in the treatment of acute lymphoblastic leukemia. It depletes plasma asparagine and glutamine, killing leukemic lymphoblasts but also causing immunosuppression. The objective of this work was to assess whether supplementing the diet with glutamine modifies the effect of asparaginase on normal lymphocyte populations in the spleen, thymus, and bone marrow. Mice consuming water ad libitum with or without alanyl-glutamine dipeptide (AlaGln; 0.05 mol/L) were injected once daily with 0 or 3 international units/g body weight Escherichia coli L-asparaginase for 7 d. Tissue expression of specific immune cell surface markers was analyzed by flow cytometry. Asparaginase reduced B220+ and sIgM+ cells in the bone marrow (P < 0.05) and diminished total cell numbers in thymus (-42%) and spleen (-53%) (P < 0.05). In thymus, asparaginase depleted double positive (CD4+CD8+) and single positive (CD4 +CD8-, CD4-CD8+) thymocytes by over 40% (P < 0.05). In spleen, asparaginase reduced CD19+ B cells to 33% of controls and substantially depleted the CD4+ and CD8+ T cell populations. CD11b-expressing leukocytes were reduced by 50% (P < 0.05). Consumption of AlaGln did not lessen the effects of asparaginase in bone marrow or thymus but mitigated cellular losses in the CD4+, CD8 +, and CD11b+ populations in spleen. AlaGln also blunted the increase in eukaryotic initiation factor 2 (eIF2) phosphorylation by asparaginase in spleen, whereas eIF2 phosphorylation did not change in thymus in response to asparaginase or AlaGln. In conclusion, asparaginase reduces maturing populations of normal B and T cells in thymus, bone marrow, and spleen. Oral consumption of AlaGln mitigates metabolic stress in spleen, supporting the peripheral immune system and cell-mediated immunity during asparaginase chemotherapy.

Original languageEnglish (US)
Pages (from-to)338-343
Number of pages6
JournalJournal of Nutrition
Volume138
Issue number2
StatePublished - Feb 1 2008

Fingerprint

alanylglutamine
asparaginase
Asparaginase
glutamine
lymphocytes
Lymphocytes
mice
spleen
Thymus Gland
Population
Spleen
bone marrow
Eukaryotic Initiation Factor-2
Bone Marrow
Glutamine
B-lymphocytes
phosphorylation
T-lymphocytes
B-Lymphocytes
Phosphorylation

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics

Cite this

Alanyl-glutamine consumption modifies the suppressive effect of L-asparaginase on lymphocyte populations in mice. / Bunpo, Piyawan; Murray, Betty; Cundiff, Judy; Brizius, Emma; Aldrich, Carla J.; Anthony, Tracy G.

In: Journal of Nutrition, Vol. 138, No. 2, 01.02.2008, p. 338-343.

Research output: Contribution to journalArticle

Bunpo, P, Murray, B, Cundiff, J, Brizius, E, Aldrich, CJ & Anthony, TG 2008, 'Alanyl-glutamine consumption modifies the suppressive effect of L-asparaginase on lymphocyte populations in mice', Journal of Nutrition, vol. 138, no. 2, pp. 338-343.
Bunpo, Piyawan ; Murray, Betty ; Cundiff, Judy ; Brizius, Emma ; Aldrich, Carla J. ; Anthony, Tracy G. / Alanyl-glutamine consumption modifies the suppressive effect of L-asparaginase on lymphocyte populations in mice. In: Journal of Nutrition. 2008 ; Vol. 138, No. 2. pp. 338-343.
@article{3e0b2a5d8f5149dbad1682f2ce4a423f,
title = "Alanyl-glutamine consumption modifies the suppressive effect of L-asparaginase on lymphocyte populations in mice",
abstract = "Asparaginase (Elspar) is used in the treatment of acute lymphoblastic leukemia. It depletes plasma asparagine and glutamine, killing leukemic lymphoblasts but also causing immunosuppression. The objective of this work was to assess whether supplementing the diet with glutamine modifies the effect of asparaginase on normal lymphocyte populations in the spleen, thymus, and bone marrow. Mice consuming water ad libitum with or without alanyl-glutamine dipeptide (AlaGln; 0.05 mol/L) were injected once daily with 0 or 3 international units/g body weight Escherichia coli L-asparaginase for 7 d. Tissue expression of specific immune cell surface markers was analyzed by flow cytometry. Asparaginase reduced B220+ and sIgM+ cells in the bone marrow (P < 0.05) and diminished total cell numbers in thymus (-42{\%}) and spleen (-53{\%}) (P < 0.05). In thymus, asparaginase depleted double positive (CD4+CD8+) and single positive (CD4 +CD8-, CD4-CD8+) thymocytes by over 40{\%} (P < 0.05). In spleen, asparaginase reduced CD19+ B cells to 33{\%} of controls and substantially depleted the CD4+ and CD8+ T cell populations. CD11b-expressing leukocytes were reduced by 50{\%} (P < 0.05). Consumption of AlaGln did not lessen the effects of asparaginase in bone marrow or thymus but mitigated cellular losses in the CD4+, CD8 +, and CD11b+ populations in spleen. AlaGln also blunted the increase in eukaryotic initiation factor 2 (eIF2) phosphorylation by asparaginase in spleen, whereas eIF2 phosphorylation did not change in thymus in response to asparaginase or AlaGln. In conclusion, asparaginase reduces maturing populations of normal B and T cells in thymus, bone marrow, and spleen. Oral consumption of AlaGln mitigates metabolic stress in spleen, supporting the peripheral immune system and cell-mediated immunity during asparaginase chemotherapy.",
author = "Piyawan Bunpo and Betty Murray and Judy Cundiff and Emma Brizius and Aldrich, {Carla J.} and Anthony, {Tracy G.}",
year = "2008",
month = "2",
day = "1",
language = "English (US)",
volume = "138",
pages = "338--343",
journal = "Journal of Nutrition",
issn = "0022-3166",
publisher = "American Society for Nutrition",
number = "2",

}

TY - JOUR

T1 - Alanyl-glutamine consumption modifies the suppressive effect of L-asparaginase on lymphocyte populations in mice

AU - Bunpo, Piyawan

AU - Murray, Betty

AU - Cundiff, Judy

AU - Brizius, Emma

AU - Aldrich, Carla J.

AU - Anthony, Tracy G.

PY - 2008/2/1

Y1 - 2008/2/1

N2 - Asparaginase (Elspar) is used in the treatment of acute lymphoblastic leukemia. It depletes plasma asparagine and glutamine, killing leukemic lymphoblasts but also causing immunosuppression. The objective of this work was to assess whether supplementing the diet with glutamine modifies the effect of asparaginase on normal lymphocyte populations in the spleen, thymus, and bone marrow. Mice consuming water ad libitum with or without alanyl-glutamine dipeptide (AlaGln; 0.05 mol/L) were injected once daily with 0 or 3 international units/g body weight Escherichia coli L-asparaginase for 7 d. Tissue expression of specific immune cell surface markers was analyzed by flow cytometry. Asparaginase reduced B220+ and sIgM+ cells in the bone marrow (P < 0.05) and diminished total cell numbers in thymus (-42%) and spleen (-53%) (P < 0.05). In thymus, asparaginase depleted double positive (CD4+CD8+) and single positive (CD4 +CD8-, CD4-CD8+) thymocytes by over 40% (P < 0.05). In spleen, asparaginase reduced CD19+ B cells to 33% of controls and substantially depleted the CD4+ and CD8+ T cell populations. CD11b-expressing leukocytes were reduced by 50% (P < 0.05). Consumption of AlaGln did not lessen the effects of asparaginase in bone marrow or thymus but mitigated cellular losses in the CD4+, CD8 +, and CD11b+ populations in spleen. AlaGln also blunted the increase in eukaryotic initiation factor 2 (eIF2) phosphorylation by asparaginase in spleen, whereas eIF2 phosphorylation did not change in thymus in response to asparaginase or AlaGln. In conclusion, asparaginase reduces maturing populations of normal B and T cells in thymus, bone marrow, and spleen. Oral consumption of AlaGln mitigates metabolic stress in spleen, supporting the peripheral immune system and cell-mediated immunity during asparaginase chemotherapy.

AB - Asparaginase (Elspar) is used in the treatment of acute lymphoblastic leukemia. It depletes plasma asparagine and glutamine, killing leukemic lymphoblasts but also causing immunosuppression. The objective of this work was to assess whether supplementing the diet with glutamine modifies the effect of asparaginase on normal lymphocyte populations in the spleen, thymus, and bone marrow. Mice consuming water ad libitum with or without alanyl-glutamine dipeptide (AlaGln; 0.05 mol/L) were injected once daily with 0 or 3 international units/g body weight Escherichia coli L-asparaginase for 7 d. Tissue expression of specific immune cell surface markers was analyzed by flow cytometry. Asparaginase reduced B220+ and sIgM+ cells in the bone marrow (P < 0.05) and diminished total cell numbers in thymus (-42%) and spleen (-53%) (P < 0.05). In thymus, asparaginase depleted double positive (CD4+CD8+) and single positive (CD4 +CD8-, CD4-CD8+) thymocytes by over 40% (P < 0.05). In spleen, asparaginase reduced CD19+ B cells to 33% of controls and substantially depleted the CD4+ and CD8+ T cell populations. CD11b-expressing leukocytes were reduced by 50% (P < 0.05). Consumption of AlaGln did not lessen the effects of asparaginase in bone marrow or thymus but mitigated cellular losses in the CD4+, CD8 +, and CD11b+ populations in spleen. AlaGln also blunted the increase in eukaryotic initiation factor 2 (eIF2) phosphorylation by asparaginase in spleen, whereas eIF2 phosphorylation did not change in thymus in response to asparaginase or AlaGln. In conclusion, asparaginase reduces maturing populations of normal B and T cells in thymus, bone marrow, and spleen. Oral consumption of AlaGln mitigates metabolic stress in spleen, supporting the peripheral immune system and cell-mediated immunity during asparaginase chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=38949183325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38949183325&partnerID=8YFLogxK

M3 - Article

C2 - 18203901

AN - SCOPUS:38949183325

VL - 138

SP - 338

EP - 343

JO - Journal of Nutrition

JF - Journal of Nutrition

SN - 0022-3166

IS - 2

ER -